What is thyroid eye disease?

Thyroid eye disease (TED), also called Graves orbitopathy or Graves ophthalmopathy, is an autoimmune condition that affects the muscles and tissues around the eyes. It causes the eyes to bulge forward (proptosis), the eyelids to retract, the eyes to become red and dry, and in many patients to develop double vision. Severe cases can threaten vision through pressure on the optic nerve.

Why it is linked to thyroid problems. Most patients with TED have or have had Graves disease, an autoimmune cause of an overactive thyroid. The same autoimmune attack that affects the thyroid gland also targets tissues in the orbit (the bony socket around the eye). The two conditions are linked but can occur on different timelines: TED can develop before, during, or after the thyroid disease itself, sometimes years apart.

The two phases. TED has an active inflammatory phase, typically lasting 18 to 24 months, during which the orbital tissues are actively inflamed and changes happen relatively quickly. After the active phase, the disease enters a stable phase, where inflammation has settled but residual changes (proptosis, lid retraction, scarred eye muscles causing double vision) may remain.

The therapy options.

For active disease: teprotumumab is a medicine targeting the IGF-1 receptor that is involved in the orbital tissue inflammation. It is given as a series of intravenous infusions and substantially reduces proptosis and double vision in active disease. Intravenous corticosteroids are an alternative, particularly when teprotumumab is not appropriate. Other immunosuppressants (mycophenolate, rituximab, tocilizumab) have evidence in active disease. Newer IGF-1R-targeted medicines and other mechanism classes are in late-stage trials.

For stable disease: surgery is often the right approach for residual changes. Orbital decompression creates more space behind the eye to reduce proptosis and pressure. Strabismus surgery corrects double vision from scarred eye muscles. Eyelid surgery addresses lid retraction.

What to expect. TED is now substantially more treatable than it was before teprotumumab. With appropriate therapy in the active phase and surgery as needed in the stable phase, most patients have meaningful improvement in appearance, eye function, and quality of life. Coordination between endocrinology (managing the thyroid disease) and ophthalmology (managing the orbital complications) shapes outcomes; integrated TED clinics deliver this coordination most effectively.